Edgewise Therapeutics reports continued successful drug trials, $17.4M loss in third quarter November 3, 20223:15:15 pm
Edgewise Therapeutics receives FDA approval for muscular dystrophy drug trials, launches stock offering September 13, 20223:38:02 pm
Edgewise reports positive interim results from Becker muscular dystrophy treatment trial Health Care & Insurance June 20, 20221:02:49 pm
Edgewise to begin Phase 2 trials for muscular dystrophy drug this year Health Care & Insurance May 11, 20229:09:48 pm
